Show simple item record

dc.contributor.authorNduva, George M
dc.contributor.authorOtieno, Frederick
dc.contributor.authorKimani, Joshua
dc.contributor.authorSein, Yiakon
dc.contributor.authorArimide, Dawit A
dc.contributor.authorMckinnon, Lyle R
dc.contributor.authorCholette, Francois
dc.contributor.authorLawrence, Morris K
dc.contributor.authorMajiwa, Maxwell
dc.contributor.authorMasika, Moses
dc.contributor.authorMutua, Gaudensia
dc.contributor.authorAnzala, Omu
dc.contributor.authorGraham, Susan M
dc.contributor.authorGelmon, Larry
dc.contributor.authorPrice, Matt A
dc.contributor.authorSmith, Adrian D
dc.contributor.authorBailey, Robert C
dc.contributor.authorMedstrand, Patrik
dc.contributor.authorSanders, Eduard J
dc.contributor.authorJoakim, Esbjörnsson
dc.contributor.authorHassan, Amin S
dc.date.accessioned2024-03-24T11:44:46Z
dc.date.available2024-03-24T11:44:46Z
dc.date.issued2024
dc.identifier.citationNduva GM, Otieno F, Kimani J, Sein Y, Arimide DA, Mckinnon LR, Cholette F, Lawrence MK, Majiwa M, Masika M, Mutua G, Anzala O, Graham SM, Gelmon L, Price MA, Smith AD, Bailey RC, Medstrand P, Sanders EJ, Esbjörnsson J, Hassan AS. Temporal trends and transmission dynamics of pre-treatment HIV-1 drug resistance within and between risk groups in Kenya, 1986-2020. J Antimicrob Chemother. 2024 Feb 1;79(2):287-296. doi: 10.1093/jac/dkad375. PMID: 38091580; PMCID: PMC10832587.en_US
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10832587/
dc.identifier.urihttp://erepository.uonbi.ac.ke/handle/11295/164386
dc.description.abstractBackground: Evidence on the distribution of pre-treatment HIV-1 drug resistance (HIVDR) among risk groups is limited in Africa. We assessed the prevalence, trends and transmission dynamics of pre-treatment HIVDR within and between MSM, people who inject drugs (PWID), female sex workers (FSWs), heterosexuals (HETs) and perinatally infected children in Kenya. Methods: HIV-1 partial pol sequences from antiretroviral-naive individuals collected from multiple sources between 1986 and 2020 were used. Pre-treatment reverse transcriptase inhibitor (RTI), PI and integrase inhibitor (INSTI) mutations were assessed using the Stanford HIVDR database. Phylogenetic methods were used to determine and date transmission clusters. Results: Of 3567 sequences analysed, 550 (15.4%, 95% CI: 14.2-16.6) had at least one pre-treatment HIVDR mutation, which was most prevalent amongst children (41.3%), followed by PWID (31.0%), MSM (19.9%), FSWs (15.1%) and HETs (13.9%). Overall, pre-treatment HIVDR increased consistently, from 6.9% (before 2005) to 24.2% (2016-20). Among HETs, pre-treatment HIVDR increased from 6.6% (before 2005) to 20.2% (2011-15), but dropped to 6.5% (2016-20). Additionally, 32 clusters with shared pre-treatment HIVDR mutations were identified. The majority of clusters had R0 ≥ 1.0, indicating ongoing transmissions. The largest was a K103N cluster involving 16 MSM sequences sampled between 2010 and 2017, with an estimated time to the most recent common ancestor (tMRCA) of 2005 [95% higher posterior density (HPD), 2000-08], indicating propagation over 12 years. Conclusions: Compared to HETs, children and key populations had higher levels of pre-treatment HIVDR. Introduction of INSTIs after 2017 may have abrogated the increase in pre-treatment RTI mutations, albeit in the HET population only. Taken together, our findings underscore the need for targeted efforts towards equitable access to ART for children and key populations in Kenya.en_US
dc.language.isoenen_US
dc.publisherUniversity of Nairobien_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.titleTemporal trends and transmission dynamics of pre-treatment HIV-1 drug resistance within and between risk groups in Kenya, 1986-2020en_US
dc.typeArticleen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States